株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のステント市場:米国・EU・日本・インド・中国・その他の地域における薬剤溶出性ステント・地金ステント市場

The World Market for Stents (Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROW)

発行 Kalorama Information 商品コード 253834
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
世界のステント市場:米国・EU・日本・インド・中国・その他の地域における薬剤溶出性ステント・地金ステント市場 The World Market for Stents (Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROW)
出版日: 2012年10月26日 ページ情報: 英文 164 Pages
概要

冠状動脈ステント産業はイノベーションが急速に進み、急展開で技術環境が進化する競合の厳しい市場です。世界人口の高齢化や長寿命化により、冠動脈性心疾患や高血圧、糖尿病、肥満症などの併発疾患の有病率は上昇すると予測されており、冠状動脈ステントの需要を刺激するでしょう。さらに患者の間で冠動脈ステントの認知度が高まり、薬剤溶出性ステントが冠状心疾患のより効果的な治療法として認められるようになるなかで、手術件数も増加すると予測されています。生体吸収性スキャフォールドや分岐型ステント、生体分解性ポリマーステントなどの新しい技術が今後数年で主要市場に参入し、心血管インターベンションの分野でのステント利用を拡大させるでしょう。

当レポートでは、世界のステント市場の現状と見通しについて調査分析し、世界の冠動脈性心疾患の発症動向、冠動脈ステントの種類と概要、冠状動脈ステント技術の近年の進化の動向、ステントタイプ・地域/主要国別の市場概要および収益予測、主要企業および主要製品のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

  • 疾患概要
  • 心血管系疾患
  • 市場概要
  • 収益予測

第2章 心血管系疾患の概要

  • 疾患概要
  • 世界の心血管系疾患統計
  • IHDの死亡率
  • 心血管系疾患の経済的負担
  • 世界の心血管系疾患への支出額
  • 世界の虚血心臓疾患の発症率

第3章 冠状動脈ステントの概要

  • 概要
  • 再狭窄
  • ステントタイプ
  • 地金ステント
  • 第1世代の地金ステント
  • 第2世代の地金ステント
  • 第3世代の地金ステント
  • Omegaプラチナクロムステント
  • Nuloyモリブデンレニウムステント
  • 地金ステントの安全性上の課題
  • 薬剤溶出性ステント
  • 薬剤溶出性ステントで利用される薬剤タイプ
  • パクリタキセル
  • シロリムス
  • エベロリムス
  • タクロリムス
  • バイオリムスA9
  • Novolimus
  • 他の薬剤クラス
  • ポリマータイプ
  • 薬剤溶出性ステント安全性上の懸念
  • ステント血栓症
  • ポリマーの機械的問題

第4章 冠状動脈ステント技術の近年の進化

  • ポリマコーティングの低減
  • 生分解性ポリマー
  • 生分解性ポリマーのメリット・デメリット
  • 既存の生分解性ポリマー
  • ポリマーフリーまたは新しいコーティングによるの薬剤溶出性ステント
  • 生体吸収性ステント
  • 生体吸収性ポリマーステントの欠点
  • 理想のステント
  • 他の生体吸収性ステント
  • 疾患固有のステント
  • 専用分岐型ステント
  • Axxess
  • Nile Pax
  • StentysのSelf-Apposingステント
  • Taxus Petal
  • XienceのSBA(Side Branch Access)ステント
  • Sparrow
  • TaxusのLiberte Atomステント
  • Xienceのナノステント、など

第5章 産業構造・動向

  • 売上・マーケティング能力
  • 差異化戦略
  • ステント材料の改良
  • DAPT期間の短縮
  • 病変固有のステント
  • 適応拡大
  • 冠状動脈ステント市場の主な動向
  • 市場成長推進因子
  • 新たなデバイスの適応拡大
  • 急性心筋梗塞・糖尿病
  • 市場全体の成長を導く新興市場
  • 市場成長阻害因子
  • 価格の下落
  • コスト上の制約
  • 厳しい経済環境
  • 産業における主な出来事
  • 最近のM&A、など

第6章 市場収益・予測

  • ステントタイプ別市場
    • 薬剤溶出性ステント
      • 市場概要
      • 製品分析
        • Xience V
        • Promus Element/Plus
        • Resolute Integrity
      • 市場力学
      • 収益予測
    • 地金ステント市場
      • 市場概要
      • 市場力学
      • 収益予測
  • 米国
    • 市場概要
    • 収益予測
  • 欧州
    • 市場概要
    • 収益予測
  • 日本
    • 市場概要
    • 収益予測
  • 中国
    • 市場概要
    • 収益予測
  • インド
    • 市場概要
    • 収益予測
  • その他の地域

第7章 企業プロファイル

図表

目次
Product Code: KLI7180813

Abstract

The coronary stents industry is a highly competitive one in which innovation occurs rapidly and the technology landscape evolves at a fast pace. As the global population is aging and has a longer life expectancy, the prevalence of coronary heart disease and co-morbid conditions such as hypertension, diabetes and obesity is projected to rise and stimulate the demand for coronary stents. Additionally, a growing acceptance of drug-eluting stents as a more effective treatment for coronary heart disease, along with increasing awareness about coronary stents among patients, is expected to boost procedural volumes. New technologies, such as bioresorbable scaffolds, and bifurcation and biodegradable polymers stents, are projected to enter major markets in the next years and increase the utilization of stents in interventional cardiology.

Despite the challenging environment, opportunities still exist in the global market for coronary stents, as there is still a high need for non-invasive therapies with enhanced safety and efficacy, and there are various niches of the market, such as bifurcation and complex lesions, that require more extensive treatment options. Additionally, the new bioresorbable stents have the potential to eliminate the negative issues of durable polymer stents, and are therefore expected to induce a significant shift in the treatment of coronary heart disease, encouraging also more patients to undergo stent implantation surgery.

This Report, The World Market for Stents (Drug Eluting and Bare Metal Product Markets in U.S., E.U., Japan, China, India and ROW) provides a complete overview of cardiovascular disease, the role of stents in treatment, the success of bare metal and drug-eluting products, as well as market sizes and forecasts to 2017. Included in this reports coverage:

  • Market Size and Forecast -Cardiovascular Disease Statistics (Mortality, Morbidity, Cost by Country)
  • Regional Breakout of Bare Metal and Drug-Eluting Stent Markets (U.S., E.U., Japan, China, India, ROW)
  • Categorization of Drug-Eluting Stents by Polymer, Drug, Platform
  • Coronary Stents Using Biodegradable Polymers, Novel Coating and Direct Drug Application
  • Assessment of Bioresorbable Stents
  • Dedicated Bifurcation, Dedicated Small Vessel Stent Products
  • Major Competitors Market Share
  • Significant Trends in Market and Near and Long-Term Impact
  • Recent Mergers and Acquisitions
  • Key Company Profiles

The major markets of US, Europe, and Japan experienced significant challenges in recent years, including price declines, decreasing volumes of percutaneous coronary interventions, and lower penetration rates for drug-eluting stents resulted from cost constraints and reductions in healthcare budgets. Additionally, the intensified competition among manufacturers also contributed to the decline in average stent selling prices in these regions. Despite that, the market potential for coronary stents in these regions remains quite attractive, given the aging population and high longevity. However, the decreasing reimbursement rates and the intensifying competition for market share are expected to continue to lead to price declines and hamper significantly the market growth.

As part of its coverage of the stents industry, the following companies are profiled:

  • Abbott Laboratories
  • Biosensors International
  • Boston Scientific
  • Biotronik SE & Co.KG
  • CID Vascular
  • Elixir Medical Corporation
  • Medtronic
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Medical (Shanghai) Co., Ltd Minvasys
  • OrbusNeich
  • REVA Medical
  • Stentys S.A.
  • Terumo Corporation

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, science, medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical, biotechnology and contract research organizations included marketing directors, division managers, and product representatives.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Disease Overview
  • Cardiovascular Disease
  • Market Overview
  • Revenue Forecast

CHAPTER TWO: CARDIOVASCULAR DISEASE OVERVIEW

  • Disease Overview
  • Top Ten Causes of Death
  • World Cardiovascular Disease Statistics
  • Mortality Rates for IHD
  • Economic Burden of Cardiovascular Disease
  • Expenditure on Cardiovascular Disease, Worldwide
  • Prevalence of Ischemic Heart Disease

CHAPTER THREE: CORONARY STENTS OVERVIEW

  • Overview
  • Restenosis
  • Types of Stents
  • Bare Metal Stents
  • First Generation of Bare Metal Stents
  • Second Generation of Bare Metal Stents
  • Third Generation of Bare Metal Stents
  • Omega Platinum-Chromium Stent
  • Nuloy Molybdenum-Rhenium Stent
  • Safety Issues of Bare Metal Stents
  • Drug-Eluting Stents
  • Types of Drugs Used on Drug-Eluting Stents
  • Paclitaxel
  • Sirolimus
  • Everolimus
  • Tacrolimus
  • Biolimus A9
  • Novolimus
  • Other Drug Classes
  • Types of Polymers
  • Safety Concerns of Drug-Eluting Stents
  • Late Stent Thrombosis
  • Mechanical Problems of Polymers

CHAPTER FOUR: RECENT ADVANCES IN CORONARY STENTS TECHNOLOGIES

  • Reduced Polymer Coatings
  • Biodegradable Polymers
  • Advantages and Disadvantages of Biodegradable Polymers
  • Current Biodegradable Polymers Stents
  • BioMatrix
  • Nobori
  • Supralimus
  • Infinnium
  • DESyne BD stent
  • Synergy
  • MiStent
  • BioMime
  • Abrax
  • Polymer-Free and Novel Coatings Drug-eluting Stents
  • Optima Jet
  • Cre8
  • Orsiro Hybrid DES
  • EPC Capturing Technology
  • Direct Application of Drug on Stent Surface
  • Amazonia Pax
  • Yukon DES
  • BioFreedom
  • Mitsu
  • Medtronic S10 platform
  • Catania stent
  • MGuard Prime
  • Titan-2
  • Bioresorbable Stents
  • Drawbacks of Bioresorbable Polymeric Stents
  • Selected Bioresorbable Coronary Stents
  • The Absorb stent
  • Biotronik's Dreams stent
  • DESolve stent
  • ReZolve Stent
  • IDEAL stent
  • Other bioresorbable stents
  • Lesion Specific Stents
  • Dedicated Bifurcated Stents
  • Axxess
  • Nile Pax
  • Stentys Self-Apposing stent
  • Taxus Petal
  • Xience Side Branch Access
  • Sparrow
  • Taxus Liberte Atom
  • Xience nano

CHAPTER FIVE: INDUSTRY STRUCTURE & TRENDS

  • Sales and Marketing Capabilities
  • Differentiation Strategies
  • Improved Stent Materials
  • Reduced DAPT Duration
  • Lesion-Specific Stents
  • Extended Indications
  • Significant Trends In The Coronary Stents Market
  • Market Drivers
  • New devices Expanded Indications
  • Acute Myocardial Infarction and Diabetes
  • Emerging Markets Are Expected To Spur The Overall Market Growth.
  • Market Restraints
  • Price decline hampers growth in the overall market.
  • Cost Constraints
  • Difficult Economic Conditions
  • Notable Recent Industry Events
  • Recent Mergers and Acquisitions
  • Biosensors International acquired CardioMind and Devax
  • Medtronic Acquired Invatec
  • Xenogenics Corporation Acquired Bioabsorbable Therapeutics
  • Market Exits

CHAPTER SIX: MARKET REVENUES AND FORECAST

  • Market by Type of Stent
  • Drug Eluting Stents Market
  • Market Snapshot
  • Products Analysis
  • Xience V
  • Promus Element/Plus
  • Resolute Integrity
  • Market Dynamics in the Drug-Eluting Stents Segment
  • Revenue Forecast
  • Bare Metal Stents Market
  • Market Snapshot
  • Market Dynamics
  • Revenue Forecast
  • United States
  • Market Snapshot
  • Revenue Forecast
  • Europe
  • Market snapshot
  • Revenue Forecast
  • Japan
  • Market snapshot
  • Revenue forecast
  • China
  • Market Snapshot
  • Revenue forecast
  • India
  • Market snapshot
  • Revenue Forecast
  • Rest of the World
  • Revenue Forecast

CHAPTER SEVEN: COMPANY PROFILES

  • Abbott Laboratories
  • Biosensors International
  • Boston Scientific
  • Biotronik SE & Co.KG
  • CID Vascular
  • Elixir Medical Corporation
  • Medtronic
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Medical (Shanghai) Co., Ltd
  • Minvasys
  • OrbusNeich
  • REVA Medical
  • Stentys S.A.
  • Terumo Corporation

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Top Ten Causes of Death in the World by Development Level, 2008
  • Figure 1-1: Global Market Revenues Forecast 2010-2017
  • (Bare Metal Stents, Drug Eluding Stents, Total)

CHAPTER TWO: CARDIOVASCULAR DISEASE OVERVIEW

  • Table 2-1: Top Ten Causes of Death in the World by Geographical Region, 2008
  • Table 2-2: Top Ten Causes of Death in the World by Development Level, 2008
  • Table 2-3: Top Ten Causes of Death in the World in High Income Countries, 2008
  • Table 2-4: Top Ten Causes of Death in the World in Middle Income Countries, 2008
  • Table 2-5: Top Ten Causes of Death in the World in Low Income Countries, 2008
  • Figure 2-1: Percentage of Deaths Related to Cardiovascular Disease in
  • the Seven Major World Markets, 2008
  • Table 2-6: Projected Deaths from Ischemic Heart Disease (IHD) and Acute
  • Myocardial Infarction (AMI) in the Seven Major World Markets, 2012
  • Table 2-7: Age-Standardized Mortality Rates for Ischemic Heart Disease (IHD)
  • and Acute Myocardial Infarction (AMI) by Gender in the Seven Major
  • World Markets, 2009
  • Table 2-8: Estimated Total Cost of Cardiovascular Disease in Europe, 2006
  • Table 2-9: Estimated Total Cost of Cardiovascular Disease in Major Markets, 2012

CHAPTER THREE: CORONARY STENTS OVERVIEW

  • Table 3-1: Selected Marketed Bare Metal Stents, 2012
  • Table 3-2: Selected Bare Metal Coronary Stents, 2012
  • Table 3-3: Selected Marketed Drug-Eluting Stents, 2012
  • Table 3-4: Selected Features of Different Generations of Commercially
  • Available Drug-eluting Stents

CHAPTER FOUR: RECENT ADVANCES IN CORONARY STENTS TECHNOLOGIES

  • Table 4-1: Selected Coronary Stents using Biodegradable Polymers, 2012
  • Table 4-2: Selected Coronary Polymer-free and Novel Coating Stents, 2012
  • Table 4-3: Selected Direct Drug Application Coronary Stents, 2012
  • Table 4-4: Selected Coronary Polymer and Drug-free Coating Stents, 2012
  • Table 4-5: Advantages and Disadvantages of Bioresorbable Stents
  • Table 4-6: Selected Bioresorbable Coronary Stents, 2012
  • Table 4-7: Selected Dedicated Bifurcation Coronary Drug-Eluting Stents, 2012
  • Table 4-8: Selected Dedicated Small Vessels Coronary Drug-Eluting Stents, 2012
  • Table 4-9: Drug Release Parameters of Selected Drug-Eluting Stents

CHAPTER FIVE: INDUSTRY STRUCTURE

  • Table 5-1: Industry Structure - Major Competitors and Selected
  • Marketed Products, 2012
  • Table 5-2: Significant Trends in the Coronary Stents Market, 2012

CHAPTER SIX: MARKET REVENUES AND FORECAST

  • Table 6-1: Coronary Stents Estimated Global Market Shares, 2011
  • Figure 6-1: Stents Market Share, 2011
  • Table 6-2: Global Market Revenues for Coronary Stents ($ Millions)
  • Figure 6-2: Global Stents Market Forecast
  • Figure 6-3: Market Breakdown by Type of Stent (BMS, DES)
  • Figure 6-4: Drug Eluting Stents Market Shre, 2011
  • Table 6-3: Global Market Revenues for Coronary Stents ($ Millions)
  • Figure 6-5: Global Market Revenues Forecast ($ Billions)Drug-Eluting Stents, 2010-2017
  • Figure 6-6: Market Breakdown by Type of Stent (BMS, DES)
  • Figure 6-7: Market Share Bare Metal Stents
  • Table 6-4: Global Market Revenues for Coronary Bare Metal Stents, 2010-2017 (Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-8: Bare Metal Stents Market 2010-2017
  • Figure 6-9: United States Share of World Market
  • Table 6-5: U.S. Market Revenues for Coronary Stents (Bare Metal Stent, Drug Eluding Stent,Total)
  • Figure 6-10: U.S. Market Revenues for Coronary Stents(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-11: Europe Share of World Stents Market
  • Table 6-6: European Market Revenues for Coronary Stents(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-12: European Market Revenues for Coronary Stents(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-13: Japan Share of World Stents Market
  • Table 6-7: Japanese Market Revenues for Coronary Stents(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-14: Japanese Market Revenues for Coronary Stents(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-15: China Share of World Stents Market
  • Table 6-8: Market Revenues for Coronary Stents in China(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-15: Market Revenues for Coronary Stents in China(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-16: India Share of World Market
  • Table 6-9: Market Revenues for Coronary Stents in India(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-17: Market Revenues for Coronary Stents in India(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-18: Rest of World Share of World Stents Market
  • Table 6-10: Market Revenues for Coronary Stents in the Rest of the World(Bare Metal Stent, Drug Eluding Stent, Total)
  • Figure 6-19: Market Revenues for Coronary Stents in the Rest of the World(Bare Metal Stent, Drug Eluding Stent, Total)
Back to Top